<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endoscopic retrograde cholangiopancreatography (ERCP) in pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endoscopic retrograde cholangiopancreatography (ERCP) in pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endoscopic retrograde cholangiopancreatography (ERCP) in pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Suku George, MD, MPH, FACP, FACG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc F Catalano, MD, FACG, FACP, FASGE, AGAF</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas G Adler, MD, FACG, AGAF, FASGE</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2730495890"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pregnancy is associated with an increased risk of gallstone formation. For pregnant patients with gallstone disease complicated by cholangitis or choledocholithiasis (ie, the presence of gallstones within the common bile duct), endoscopic retrograde cholangiopancreatography (ERCP)-guided intervention can be performed safely and successfully.</p><p>This topic will discuss procedural considerations, strategies to minimize radiation exposure, and outcomes for pregnant patients who undergo ERCP. Other related topics are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Management of gallstone disease during pregnancy (See  <a class="medical medical_review" href="/z/d/html/15095.html" rel="external">"Gallstone diseases in pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonobstetric surgery in pregnant patients (See  <a class="medical medical_review" href="/z/d/html/121990.html" rel="external">"Nonobstetric surgery in pregnant patients: Patient counseling, surgical considerations, and obstetric management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overview of ERCP including indications, patient preparation, post-procedure care, and adverse events (See  <a class="medical medical_review" href="/z/d/html/632.html" rel="external">"Overview of endoscopic retrograde cholangiopancreatography (ERCP) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anesthesia management for patients undergoing ERCP (See  <a class="medical medical_review" href="/z/d/html/105511.html" rel="external">"Anesthesia for gastrointestinal endoscopy in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conditions that are often managed with therapeutic ERCP and a discussion of endoscopic techniques for removing bile duct stones (See  <a class="medical medical_review" href="/z/d/html/13922.html" rel="external">"Choledocholithiasis: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/658.html" rel="external">"Acute cholangitis: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/674.html" rel="external">"Endoscopic management of bile duct stones"</a>.)</p><p></p><p class="headingAnchor" id="H2352518141"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>The prevalence of cholelithiasis during pregnancy ranges from 1 to 5 percent, and approximately 1 percent of pregnant patients with gallstone disease develop symptoms [<a href="#rid1">1,2</a>]. In a large population-based study including female patients who were hospitalized for gallstone pancreatitis, nearly 8 percent of patients were pregnant [<a href="#rid3">3</a>].</p><p>In addition, biliary tract disease represents one of the most frequent indications for nonobstetric surgery during pregnancy; this is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/121990.html" rel="external">"Nonobstetric surgery in pregnant patients: Patient counseling, surgical considerations, and obstetric management"</a>.)</p><p class="headingAnchor" id="H2828620320"><span class="h1">PREPROCEDURE EVALUATION</span><span class="headingEndMark"> — </span>For most patients with gallstone disease and suspected choledocholithiasis, the preprocedure evaluation typically includes radiographic imaging (eg, abdominal ultrasound, magnetic resonance cholangiopancreatography [MRCP]) to confirm the diagnosis [<a href="#rid4">4</a>], and this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15095.html" rel="external">"Gallstone diseases in pregnancy", section on 'Diagnostic evaluation and findings'</a>.)</p><p>If the diagnosis of choledocholithiasis remains uncertain and/or MRCP cannot be performed or is equivocal, endoscopic ultrasound (EUS) is a reasonable alternative [<a href="#rid5">5,6</a>]. EUS can be performed immediately prior to ERCP, and if no biliary stones are identified, the ERCP may not be necessary. In addition, for patients in whom choledocholithiasis is confirmed with EUS, stone characteristics (eg, size, number, location) can be assessed to facilitate the ERCP procedure. (See  <a class="medical medical_review" href="/z/d/html/666.html" rel="external">"Acute calculous cholecystitis: Clinical features and diagnosis", section on 'Additional evaluation in selected patients'</a>.)</p><p class="headingAnchor" id="H3051558982"><span class="h1">PROCEDURAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H1790930991"><span class="h2">Patient preparation</span><span class="headingEndMark"> — </span>Preprocedure preparation for pregnant patients undergoing ERCP is similar to that described for nonpregnant patients undergoing ERCP (see  <a class="medical medical_review" href="/z/d/html/13928.html" rel="external">"Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)", section on 'Patient preparation'</a>). Specific issues related to pregnancy are addressed here:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient counseling</strong> – Patients should be fully informed regarding the risk of procedure-related adverse events, alternatives to ERCP, and radiation risks to themselves and the fetus. Strategies used to minimize radiation exposure are reviewed and documented. (See <a class="local">'Strategies to minimize radiation exposure'</a> below and  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>.)</p><p></p><p class="bulletIndent1">The risk of adverse obstetric events related to ERCP during pregnancy appears to be low, although published data are mostly limited to retrospective cohort studies [<a href="#rid7">7-16</a>]. (See <a class="local">'Outcomes'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specialty consultation</strong> – Care of the pregnant patient undergoing ERCP requires input from specialists in advanced endoscopy, obstetrics (usually with expertise in high-risk pregnancies), and anesthesia. The decision to monitor fetal heart rate should be individualized and depends on the gestational age of the fetus and available resources [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/121990.html" rel="external">"Nonobstetric surgery in pregnant patients: Patient counseling, surgical considerations, and obstetric management", section on 'Fetal heart rate monitoring'</a>.)</p><p></p><p class="bulletIndent1">Observational data suggest that higher volume endoscopists (ie, ≥200 ERCPs annually) compared with lower volume endoscopists are associated with lower radiation exposure per procedure [<a href="#rid18">18-20</a>]. In a large population-based study, performing ERCP at a teaching hospital compared with a nonteaching hospital was associated with lower rates of post-ERCP pancreatitis (10 versus 15 percent) [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anesthesia</strong> – For pregnant patients, we consult with an anesthesia clinician to provide sedation (typically <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>). When used in standard doses, none of the commonly used anesthetic agents (eg, propofol, <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a>, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>) have been shown to have teratogenic effects in humans [<a href="#rid17">17,21</a>]. (See  <a class="medical medical_review" href="/z/d/html/105511.html" rel="external">"Anesthesia for gastrointestinal endoscopy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/116362.html" rel="external">"Anesthesia for nondelivery obstetric procedures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic prophylaxis</strong> – The need for antibiotic prophylaxis is determined by the patient's risk factors for procedure-related infection  (<a class="graphic graphic_table graphicRef99536" href="/z/d/graphic/99536.html" rel="external">table 1</a>) and this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2545.html" rel="external">"Antibiotic prophylaxis for gastrointestinal endoscopic procedures"</a>.)</p><p></p><p class="bulletIndent1">For pregnant patients, we often prescribe either of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">Amoxicillin-clavulanate</a> 1750 mg orally within 60 minutes prior to procedure, or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">Ampicillin-sulbactam</a> 3 grams intravenously within 60 minutes prior to procedure</p><p></p><p class="bulletIndent1">Other antibiotics (eg, fluoroquinolones, aminoglycosides), which are typically used in nonpregnant patients, are generally <strong>avoided</strong> because of potential fetal or maternal toxicity. Antibiotic regimens for nonpregnant patients undergoing ERCP and a general discussion regarding the safety of certain antibiotics in pregnant patients are presented separately. (See  <a class="medical medical_review" href="/z/d/html/2545.html" rel="external">"Antibiotic prophylaxis for gastrointestinal endoscopic procedures", section on 'Antibiotic regimens'</a> and  <a class="medical medical_review" href="/z/d/html/112420.html" rel="external">"Prenatal care: Patient education, health promotion, and safety of commonly used drugs", section on 'Antibiotics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs)</strong> – While rectal NSAIDs (eg, <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> suppository) are routinely given as a single dose to nonpregnant patients prior to ERCP to reduce the risk of post-ERCP pancreatitis [<a href="#rid21">21</a>], we typically <strong>avoid</strong> using NSAID prophylaxis for pregnant patients &gt;28 weeks gestation as NSAID use may be associated with adverse pregnancy and infant outcomes (eg, oligohydramnios, premature constriction of the ductus arteriosus). However, the risk of such outcomes after a single dose is very low. For pregnant patients ≤28 weeks, single-dose NSAID prophylaxis is reasonable as the risks associated with NSAID use earlier in pregnancy appear to be low. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/629.html" rel="external">"Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis", section on 'Pharmacologic prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'NSAIDs'</a>.) </p><p></p><p class="headingAnchor" id="H2722930637"><span class="h2">Timing of ERCP</span><span class="headingEndMark"> — </span>We do not delay performing ERCP in pregnant patients when it is indicated (eg, symptomatic choledocholithiasis, cholangitis), and limited data suggest that endoscopic intervention is associated with improved outcomes [<a href="#rid3">3,22</a>].</p><p>In the database study including over 110,000 female patients who were hospitalized for gallstone pancreatitis discussed above (see <a class="local">'Prevalence'</a> above), pregnant compared with nonpregnant patients had lower rates of undergoing ERCP (21 versus 25 percent, p&lt;0.001) [<a href="#rid3">3</a>]. The overall risk of 30-day readmission was higher for pregnant compared with nonpregnant patients who were matched for age (odds ratio [OR] 1.95, 95% CI 1.67-2.3). However, for pregnant patients, ERCP during hospital admission compared with no ERCP was associated with lower risk of early readmission (OR 0.40, 95% CI 0.27-0.57) [<a href="#rid3">3</a>]. Similarly, in a retrospective study including 112 pregnant patients with symptomatic choledocholithiasis, procedural intervention (either ERCP or laparoscopic cholecystectomy) compared with medical management alone was associated with lower rates of recurrent biliary symptoms (13 versus 60 percent, p = 0.0002) [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H3893594940"><span class="h2">Radiation exposure</span><span class="headingEndMark"> — </span>Fluoroscopy is typically used during ERCP to visualize the biliary tract and to guide biliary cannulation and therapeutic interventions (eg, stone extraction). Studies suggest that fetal radiation exposure during ERCP ranges from &lt;0.0001 to 0.0057 Gy (0.1 to 5.77 mGy) [<a href="#rid7">7,10,11,23-25</a>]. Imaging studies that expose the fetus to &lt;0.05 Gy (50 mGy, 5 rads) have <strong>not</strong> been associated with increased risk of deterministic effects (eg, fetal anomalies, intellectual disability, growth restriction, pregnancy loss) from ionizing radiation at this dose level [<a href="#rid26">26,27</a>]. However, stochastic effects (eg, childhood cancers) of radiation do not exhibit any threshold dose. Thus, it is possible that smaller doses could increase the risk of childhood cancers, and long-term follow-up studies on radiation-related adverse effects are limited.</p><p>In a study including 24 children whose mothers underwent ERCP during pregnancy, there were no developmental delays or malignancies reported after a median of 11 years follow-up [<a href="#rid28">28</a>]. Fetal risks from ionizing radiation and radiation nomenclature are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients", section on 'Fetal risks'</a> and  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients", section on 'Nomenclature'</a>.)</p><p class="headingAnchor" id="H166520875"><span class="h2">Strategies to minimize radiation exposure</span></p><p class="headingAnchor" id="H821322041"><span class="h3">General measures</span><span class="headingEndMark"> — </span>Measures to reduce the risk of adverse events to the mother and fetus from radiation exposure include (see  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Utilize shielding</strong> – Proper shielding should be used to minimize radiation exposure to the uterus [<a href="#rid29">29</a>]. A radiation protection apron shield, if used, should be placed <strong>underneath</strong> the patient and not draped over the abdomen since the radiation source is typically located underneath the patient when using the standard fluoroscopy C-arm. However, external shielding cannot eliminate fetal exposure due to internally scattered radiation. The uterus should be positioned outside the primary x-ray beam.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjust patient positioning</strong> – After approximately 20 weeks of pregnancy, the typical patient positioning for ERCP (ie, prone position) is often not possible because of the gravid uterus. Thus, the left lateral decubitus position, or left pelvic tilt, is required to avoid vena cava or aortic compression [<a href="#rid17">17,30</a>]. Supporting cushions or pillows should be available, and shielding should be adjusted appropriately.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limit fluoroscopy time and radiation dose</strong> – The following measures will help limit the total fluoroscopy time and radiation dose [<a href="#rid23">23,29,31</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain static (spot) films rather than using continuous fluoroscopy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Minimize magnification of the fluoroscopic image</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Collimate the x-ray beam to the smallest possible field and use other protocols for low-dose radiation (eg, increasing tube voltage, using a low frame rate)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use "last image hold" feature to review images rather than using additional fluoroscopy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Position the image intensifier as close to the patient as possible and place the x-ray tube as far away from the patient as possible. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use fetal radiation exposure monitoring</strong> – We agree with society guidelines that advise monitoring for fetal radiation exposure if such monitoring equipment is available [<a href="#rid31">31,32</a>]. Dosimeters can be placed on the patient at the expected uterine location to record total radiation dose. Total fluoroscopy time can be recorded if desired and depending on the type of fluoroscopy equipment.</p><p></p><p>The International Commission on Radiological Protection advises monitoring fetal radiation if the dose is expected to exceed 0.01 Gy (10 mGy), which is higher than the expected fetal radiation exposure during ERCP [<a href="#rid7">7,10,11,23-25</a>] (see <a class="local">'Radiation exposure'</a> above). However, it is possible that the threshold for monitoring may be exceeded during longer and more complex procedures, and the complexity of a procedure is often difficult to predict. In an observational study including 35 pregnant patients (mean gestational age 19 weeks, range 4 to 35 weeks) who were monitored with thermoluminescent dosimeters during ERCP, the majority of patients (89 percent) had a mean fluoroscopy time of 9 seconds with an estimated fetal radiation dose of &lt;0.0002 (0.2 mGy) [<a href="#rid7">7</a>]. Three patients had fetal radiation dose ranging from 0.0002 to 0.0005 Gy (0.2 to 0.5 mGy), while one patient had fetal radiation dose &gt;0.0005 Gy (0.5 mGy). It should be noted that whether the dose recorded by dosimeters correlated well with the fetal dose is uncertain because the actual fetal doses may vary based on gestational age and the patient's body habitus. </p><p class="headingAnchor" id="H2242131274"><span class="h3">Role of ERCP without radiation</span><span class="headingEndMark"> — </span>Several investigational approaches have been described that facilitate biliary intervention but do not require fluoroscopy. These modalities may be useful for selected patients in whom radiation exposure is expected to exceed safety limits due to the complexity of the procedure: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confirming selective biliary cannulation by aspiration of bile or observing bile flow</strong> – An alternative to fluoroscopic-guided cannulation of the bile duct is to visualize bile by aspiration or by observing bile flow through the papilla. As an example, in a series of 21 pregnant patients who had ERCP, confirming bile duct cannulation was done by visually assessing for bile flowing around the wire within the papillary orifice; one case of mild post-ERCP pancreatitis was reported [<a href="#rid8">8</a>]. A limitation of a radiation-free approach is that clearance of the common bile duct cannot be confirmed after stone removal unless direct visualization of the bile duct is performed with a miniature endoscope (ie, cholangioscope). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholangioscopy</strong> – Cholangioscopy is typically performed during endoscopic therapy to facilitate extraction of difficult bile duct stones  (<a class="graphic graphic_table graphicRef138304" href="/z/d/graphic/138304.html" rel="external">table 2</a>), but it has also been used to facilitate ERCP without radiation. The bile duct can be visualized with cholangioscopy to achieve stone removal and confirm bile duct clearance [<a href="#rid6">6,8,33-35</a>]. In an observational study including 10 pregnant patients who had ERCP with cholangioscopy, bile duct cannulation was achieved in all patients without fluoroscopy, while therapeutic intervention (eg, stone extraction, stent removal) was successful without fluoroscopy in five patients (50 percent) [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/633.html" rel="external">"Cholangioscopy and pancreatoscopy"</a>.)</p><p></p><p>Potential limitations of ERCP without fluoroscopy include longer procedure times, lack of radiographic visualization to confirm bile duct cannulation, inadvertent cannulation of the cystic duct, and difficulty recognizing conditions such as bile leak, bile duct stricture, or perforation [<a href="#rid8">8</a>]. However, observational data suggested that ERCP without fluoroscopy in pregnant patients was safe and effective. In a systematic review of 27 studies including 1307 pregnant patients who underwent ERCP, radiation-free ERCP was associated with lower overall rates of nonpregnancy-related adverse events (eg, gastrointestinal bleeding, post-ERCP pancreatitis) compared with standard-radiation technique (8 versus 15 percent, respectively) [<a href="#rid18">18</a>]. Rates of fetal or pregnancy-related adverse events were similar between groups. In a systematic review of eight studies including 147 pregnant patients who had ERCP without fluoroscopy, technical success rates were high (≥95 percent), while techniques to avoid radiation exposure varied among studies [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1151021915"><span class="h1">POSTPROCEDURE CARE</span><span class="headingEndMark"> — </span>General considerations for the postprocedure care for pregnant patients (eg, maternal and fetal monitoring) are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6775.html" rel="external">"Anesthesia for nonobstetric surgery during pregnancy", section on 'Postoperative care'</a>.)</p><p>Following ERCP, the patient can usually resume drinking clear fluids after the effects of anesthesia have subsided and then advance to a regular diet as tolerated.</p><p class="headingAnchor" id="H1201510886"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H1630119655"><span class="h2">Maternal outcomes</span><span class="headingEndMark"> — </span>Data from mostly smaller retrospective studies suggest that ERCP during pregnancy appears to be safe for the mother and fetus [<a href="#rid3">3,7-16,19,37</a>]. In addition, delaying endoscopic intervention has been associated with increased risk of adverse events (eg, hospital readmission for biliary colic) [<a href="#rid3">3,22</a>]. Thus, pregnant patients who require ERCP should be advised to proceed and avoid delay.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ERCP pancreatitis</strong> – Data suggest that pregnancy may be a risk factor for post-ERCP pancreatitis. In a registry study including 3628 female patients who underwent ERCP, the risk of post-ERCP pancreatitis was higher for pregnant (907 patients) compared with nonpregnant patients (12 versus 5 percent; adjusted odds ratio [OR] 2.8, 95% CI 2.1-3.8) [<a href="#rid19">19</a>]. This is consistent with data from smaller retrospective studies, which also report a higher incidence of post-ERCP pancreatitis among pregnant patients compared with the general population (range: 5 to 16 percent versus 3 to 10 percent, respectively) [<a href="#rid9">9,36,38</a>]. Whether there is a physiologic basis for increased risk of post-ERCP pancreatitis during pregnancy is uncertain, although some prophylactic strategies (eg, NSAIDs) that are used for nonpregnant patients are not typically used during pregnancy. (See <a class="local">'Patient preparation'</a> above.) </p><p></p><p class="bulletIndent1">Risk factors for post-ERCP pancreatitis and strategies for prophylaxis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/629.html" rel="external">"Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal death</strong> – Maternal death related to ERCP is rare. Among 11 studies including nearly 350 patients who had ERCP during pregnancy [<a href="#rid7">7-16,30</a>], one case of maternal mortality related to post-ERCP pancreatitis that was complicated by acute respiratory distress syndrome was reported [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other ERCP-related events</strong> – Pregnancy does not appear to increase other ERCP-related events (eg, perforation, gastrointestinal bleeding, cholangitis, need for percutaneous drainage) [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H270674272"><span class="h2">Fetal outcomes</span><span class="headingEndMark"> — </span>ERCP during pregnancy has not been associated with an overall increased risk of adverse obstetric or fetal outcomes. However, studies are mostly limited to pregnancy and the immediate postpartum period and do not include longer term follow-up [<a href="#rid18">18,19,37</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal distress or fetal loss</strong> – ERCP does not appear to be associated with fetal distress or fetal loss. In the registry study including 907 pregnant patients who underwent ERCP discussed above (see <a class="local">'Maternal outcomes'</a> above), rates of fetal distress or fetal loss were low (0.33 and 0.67 percent, respectively), and these rates were similar to the general obstetric population [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premature labor and/or birth</strong> – ERCP also does not appear to be associated with an increased risk of premature labor and/or birth. In the registry study discussed above, estimated rates of preterm labor were lower compared with the general population (1.9 versus 11.5 percent) [<a href="#rid19">19</a>].  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal death</strong> – Neonatal death is rare, but data are limited. In a series including 23 pregnant patients undergoing ERCP, the only neonatal death was reported in a patient who had three ERCPs during the same pregnancy with minor papilla sphincterotomy and stenting. Each ERCP was complicated by acute pancreatitis requiring inpatient hospitalization [<a href="#rid30">30</a>]. This study illustrates the importance of avoiding multiple ERCPs during pregnancy, if possible. </p><p></p><p class="headingAnchor" id="H4205194104"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118263.html" rel="external">"Society guideline links: Endoscopic retrograde cholangiopancreatography (ERCP)"</a>.)</p><p class="headingAnchor" id="H2128343343"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Pregnancy is associated with an increased risk of gallstone formation. For pregnant patients with gallstone disease complicated by choledocholithiasis (ie, the presence of gallstones within the common bile duct) or cholangitis, endoscopic retrograde cholangiopancreatography (ERCP)-guided intervention can be performed safely and successfully. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preprocedure evaluation</strong> – For most patients with suspected choledocholithiasis, the preprocedure evaluation typically includes radiographic imaging (eg, abdominal ultrasound, magnetic resonance cholangiopancreatography [MRCP]) to confirm the diagnosis. If the diagnosis of choledocholithiasis remains uncertain and/or MRCP cannot be performed, endoscopic ultrasound (EUS) is a reasonable alternative. (See <a class="local">'Preprocedure evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/13922.html" rel="external">"Choledocholithiasis: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient preparation</strong> – The preprocedure preparation for pregnant patients undergoing ERCP is similar to that described for nonpregnant patients. Issues specific to pregnancy include (see <a class="local">'Patient preparation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multidisciplinary care</strong> – Care of the pregnant patient undergoing ERCP requires input from specialists in advanced endoscopy, obstetrics (usually with expertise in high-risk pregnancies), and anesthesia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NSAIDs</strong> – For pregnant patients &gt;28 weeks gestation, we suggest <strong>against</strong> pharmacologic prophylaxis with nonsteroidal anti-inflammatory drugs (NSAIDs) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). While some evidence suggests that a single dose of rectally administered NSAID reduces the risk of post-ERCP pancreatitis, NSAIDs have been associated with adverse pregnancy and infant outcomes (eg, oligohydramnios, premature constriction of the ductus arteriosus). However, the risk of such outcomes after a single dose is very low. For pregnant patients ≤28 weeks, single-dose NSAID prophylaxis is reasonable as the risks associated with NSAID use earlier in pregnancy appear to be low. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotic prophylaxis</strong> – Recommendations for antibiotic prophylaxis are based on a patient's risk factors for procedure-related infection  (<a class="graphic graphic_table graphicRef99536" href="/z/d/graphic/99536.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2">When antibiotic prophylaxis is recommended, we often prescribe <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> <strong>or</strong> <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> within 60 minutes prior to procedure.<strong> </strong>Other antibiotics (eg, fluoroquinolones, aminoglycosides), which are typically used in nonpregnant patients, are generally <strong>avoided</strong> because of potential fetal or maternal toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation exposure</strong> – Fluoroscopy is typically used during ERCP to visualize the biliary tract and to guide biliary cannulation and therapeutic interventions (eg, stone extraction). In general, fetal radiation exposure during ERCP is lower than 0.05 Gy and thus is not associated with an increased risk of fetal anomalies, intellectual disability, growth restriction, or pregnancy loss. (See <a class="local">'Radiation exposure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measures to reduce the risk of adverse events to the mother and fetus from radiation exposure include shielding, limiting fluoroscopy time, obtaining static (spot) films, collimating the x-ray beam to the smallest possible field, and using a low frame rate. (See <a class="local">'Strategies to minimize radiation exposure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several techniques have also been studied and show promise for reducing the need for fluoroscopy during ERCP. These include the use of visualization of bile to confirm biliary cannulation and use of cholangioscopy (ie, direct endoscopic visualization of the bile duct with a miniature endoscope). (See <a class="local">'Role of ERCP without radiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – ERCP during pregnancy appears to be safe for the mother and fetus. Specifically, ERCP is not associated with increased risk of premature labor and/or birth compared with the general obstetrical population. In addition, delaying endoscopic intervention has been associated with increased risk of adverse events (eg, hospital readmission for biliary colic). (See <a class="local">'Outcomes'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ibiebele I, Schnitzler M, Nippita T, Ford JB. Outcomes of Gallstone Disease during Pregnancy: a Population-based Data Linkage Study. Paediatr Perinat Epidemiol 2017; 31:522.</a></li><li><a class="nounderline abstract_t">Anita C, Kumar P, Malathi S, et al. Gallstones in pregnancy--a prevalence study from India. J Clin Gastroenterol 2008; 42:1065.</a></li><li><a class="nounderline abstract_t">Luthra AK, Patel KP, Li F, et al. Endoscopic intervention and cholecystectomy in pregnant women with acute biliary pancreatitis decrease early readmissions. Gastrointest Endosc 2019; 89:1169.</a></li><li><a class="nounderline abstract_t">Moon JH, Cho YD, Cha SW, et al. The detection of bile duct stones in suspected biliary pancreatitis: comparison of MRCP, ERCP, and intraductal US. Am J Gastroenterol 2005; 100:1051.</a></li><li><a class="nounderline abstract_t">Vohra S, Holt EW, Bhat YM, et al. Successful single-session endosonography-based endoscopic retrograde cholangiopancreatography without fluoroscopy in pregnant patients with suspected choledocholithiasis: a case series. J Hepatobiliary Pancreat Sci 2014; 21:93.</a></li><li><a class="nounderline abstract_t">Sethi S, Thosani N, Banerjee S. Radiation-Free ERCP in Pregnancy: A "Sound" Approach to Leaving No Stone Unturned. Dig Dis Sci 2015; 60:2604.</a></li><li><a class="nounderline abstract_t">Smith I, Gaidhane M, Goode A, Kahaleh M. Safety of endoscopic retrograde cholangiopancreatography in pregnancy: Fluoroscopy time and fetal exposure, does it matter? World J Gastrointest Endosc 2013; 5:148.</a></li><li><a class="nounderline abstract_t">Shelton J, Linder JD, Rivera-Alsina ME, Tarnasky PR. Commitment, confirmation, and clearance: new techniques for nonradiation ERCP during pregnancy (with videos). Gastrointest Endosc 2008; 67:364.</a></li><li><a class="nounderline abstract_t">Tang SJ, Mayo MJ, Rodriguez-Frias E, et al. Safety and utility of ERCP during pregnancy. Gastrointest Endosc 2009; 69:453.</a></li><li><a class="nounderline abstract_t">Kahaleh M, Hartwell GD, Arseneau KO, et al. Safety and efficacy of ERCP in pregnancy. Gastrointest Endosc 2004; 60:287.</a></li><li><a class="nounderline abstract_t">Tham TC, Vandervoort J, Wong RC, et al. Safety of ERCP during pregnancy. Am J Gastroenterol 2003; 98:308.</a></li><li><a class="nounderline abstract_t">Gupta R, Tandan M, Lakhtakia S, et al. Safety of therapeutic ERCP in pregnancy - an Indian experience. Indian J Gastroenterol 2005; 24:161.</a></li><li><a class="nounderline abstract_t">Ersoz G, Turan I, Tekin F, et al. Nonradiation ERCP with endoscopic biliary sphincterotomy plus papillary balloon dilation for the treatment of choledocholithiasis during pregnancy. Surg Endosc 2016; 30:222.</a></li><li><a class="nounderline abstract_t">Fine S, Beirne J, Delgi-Esposti S, Habr F. Continued evidence for safety of endoscopic retrograde cholangiopancreatography during pregnancy. World J Gastrointest Endosc 2014; 6:352.</a></li><li><a class="nounderline abstract_t">Yang J, Zhang X, Zhang X. Therapeutic efficacy of endoscopic retrograde cholangiopancreatography among pregnant women with severe acute biliary pancreatitis. J Laparoendosc Adv Surg Tech A 2013; 23:437.</a></li><li><a class="nounderline abstract_t">Huang P, Zhang H, Zhang XF, et al. Individualized endoscopic treatment for pregnant patients with acute pancreaticobiliary diseases. J Health Res Rev 2017; 4:13.</a></li><li><a class="nounderline abstract_t">ASGE Standard of Practice Committee, Shergill AK, Ben-Menachem T, et al. Guidelines for endoscopy in pregnant and lactating women. Gastrointest Endosc 2012; 76:18.</a></li><li><a class="nounderline abstract_t">Azab M, Bharadwaj S, Jayaraj M, et al. Safety of endoscopic retrograde cholangiopancreatography (ERCP) in pregnancy: A systematic review and meta-analysis. Saudi J Gastroenterol 2019; 25:341.</a></li><li><a class="nounderline abstract_t">Inamdar S, Berzin TM, Sejpal DV, et al. Pregnancy is a Risk Factor for Pancreatitis After Endoscopic Retrograde Cholangiopancreatography in a National Cohort Study. Clin Gastroenterol Hepatol 2016; 14:107.</a></li><li><a class="nounderline abstract_t">Liao C, Thosani N, Kothari S, et al. Radiation exposure to patients during ERCP is significantly higher with low-volume endoscopists. Gastrointest Endosc 2015; 81:391.</a></li><li><a class="nounderline abstract_t">Cappell MS. The fetal safety and clinical efficacy of gastrointestinal endoscopy during pregnancy. Gastroenterol Clin North Am 2003; 32:123.</a></li><li><a class="nounderline abstract_t">Othman MO, Stone E, Hashimi M, Parasher G. Conservative management of cholelithiasis and its complications in pregnancy is associated with recurrent symptoms and more emergency department visits. Gastrointest Endosc 2012; 76:564.</a></li><li><a class="nounderline abstract_t">Magno-Pereira V, Moutinho-Ribeiro P, Macedo G. Demystifying endoscopic retrograde cholangiopancreatography (ERCP) during pregnancy. Eur J Obstet Gynecol Reprod Biol 2017; 219:35.</a></li><li><a class="nounderline abstract_t">Huda A, Garzón WJ, Filho GC, et al. Evaluation of staff, patient and foetal radiation doses due to endoscopic retrograde cholangiopancreatography (ERCP) procedures in a pregnant patient. Radiat Prot Dosimetry 2016; 168:401.</a></li><li class="breakAll">Annals of the International Commission on Radiological Protection. Pregnancy and Medical Radiation. 2000. https://journals.sagepub.com/doi/pdf/10.1177/ANIB_30_1 (Accessed on April 25, 2022).</li><li><a class="nounderline abstract_t">Brent RL. The effect of embryonic and fetal exposure to x-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks. Semin Oncol 1989; 16:347.</a></li><li class="breakAll">Radiation and Pregnancy: A Fact Sheet for Clinicians. Centers for Disease Control and Prevention. Available at: https://emergency.cdc.gov/radiation/prenatalphysician.asp (Accessed on November 08, 2017).</li><li><a class="nounderline abstract_t">Laudanno O, Garrido J, Ahumarán G, et al. Long-term follow-up after fetal radiation exposure during endoscopic retrograde cholangiopancreatography. Endosc Int Open 2020; 8:E1909.</a></li><li><a class="nounderline abstract_t">Kwok K, Hasan N, Duloy A, et al. American Society for Gastrointestinal Endoscopy radiation and fluoroscopy safety in GI endoscopy. Gastrointest Endosc 2021; 94:685.</a></li><li><a class="nounderline abstract_t">Jamidar PA, Beck GJ, Hoffman BJ, et al. Endoscopic retrograde cholangiopancreatography in pregnancy. Am J Gastroenterol 1995; 90:1263.</a></li><li><a class="nounderline abstract_t">Dumonceau JM, Garcia-Fernandez FJ, Verdun FR, et al. Radiation protection in digestive endoscopy: European Society of Digestive Endoscopy (ESGE) guideline. Endoscopy 2012; 44:408.</a></li><li><a class="nounderline abstract_t">Di Leo M, Arcidiacono PG. Fetal radiation exposure: Is monitoring really needed? World J Gastrointest Endosc 2013; 5:366.</a></li><li><a class="nounderline abstract_t">Girotra M, Jani N. Role of endoscopic ultrasound/SpyScope in diagnosis and treatment of choledocholithiasis in pregnancy. World J Gastroenterol 2010; 16:3601.</a></li><li><a class="nounderline abstract_t">Uradomo L, Pandolfe F, Aragon G, Borum ML. SpyGlass cholangioscopy for management of choledocholithiasis during pregnancy. Hepatobiliary Pancreat Dis Int 2011; 10:107.</a></li><li><a class="nounderline abstract_t">Brewer Gutierrez OI, Godoy Brewer G, Zulli C, et al. Multicenter experience with digital single-operator cholangioscopy in pregnant patients. Endosc Int Open 2021; 9:E116.</a></li><li><a class="nounderline abstract_t">Cappell MS, Stavropoulos SN, Friedel D. Systematic review of safety and efficacy of therapeutic endoscopic-retrograde-cholangiopancreatography during pregnancy including studies of radiation-free therapeutic endoscopic-retrograde-cholangiopancreatography. World J Gastrointest Endosc 2018; 10:308.</a></li><li><a class="nounderline abstract_t">Ludvigsson JF, Lebwohl B, Ekbom A, et al. Outcomes of Pregnancies for Women Undergoing Endoscopy While They Were Pregnant: A Nationwide Cohort Study. Gastroenterology 2017; 152:554.</a></li><li><a class="nounderline abstract_t">Kochar B, Akshintala VS, Afghani E, et al. Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials. Gastrointest Endosc 2015; 81:143.</a></li></ol></div><div id="topicVersionRevision">Topic 653 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28881393" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Outcomes of Gallstone Disease during Pregnancy: a Population-based Data Linkage Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18596540" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gallstones in pregnancy--a prevalence study from India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30503844" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Endoscopic intervention and cholecystectomy in pregnant women with acute biliary pancreatitis decrease early readmissions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842578" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The detection of bile duct stones in suspected biliary pancreatitis: comparison of MRCP, ERCP, and intraductal US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23798477" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Successful single-session endosonography-based endoscopic retrograde cholangiopancreatography without fluoroscopy in pregnant patients with suspected choledocholithiasis: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577267" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Radiation-Free ERCP in Pregnancy: A "Sound" Approach to Leaving No Stone Unturned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23596536" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Safety of endoscopic retrograde cholangiopancreatography in pregnancy: Fluoroscopy time and fetal exposure, does it matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18226705" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Commitment, confirmation, and clearance: new techniques for nonradiation ERCP during pregnancy (with videos).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19136111" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Safety and utility of ERCP during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15278066" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Safety and efficacy of ERCP in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12591046" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Safety of ERCP during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16204904" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Safety of therapeutic ERCP in pregnancy - an Indian experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25840897" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nonradiation ERCP with endoscopic biliary sphincterotomy plus papillary balloon dilation for the treatment of choledocholithiasis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25132918" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Continued evidence for safety of endoscopic retrograde cholangiopancreatography during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23452176" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Therapeutic efficacy of endoscopic retrograde cholangiopancreatography among pregnant women with severe acute biliary pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Individualized endoscopic treatment for pregnant patients with acute pancreaticobiliary diseases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22579258" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Guidelines for endoscopy in pregnant and lactating women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31744939" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Safety of endoscopic retrograde cholangiopancreatography (ERCP) in pregnancy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25952311" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pregnancy is a Risk Factor for Pancreatitis After Endoscopic Retrograde Cholangiopancreatography in a National Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25293825" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Radiation exposure to patients during ERCP is significantly higher with low-volume endoscopists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12635415" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The fetal safety and clinical efficacy of gastrointestinal endoscopy during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22732875" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Conservative management of cholelithiasis and its complications in pregnancy is associated with recurrent symptoms and more emergency department visits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29040894" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Demystifying endoscopic retrograde cholangiopancreatography (ERCP) during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26084305" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evaluation of staff, patient and foetal radiation doses due to endoscopic retrograde cholangiopancreatography (ERCP) procedures in a pregnant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26084305" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evaluation of staff, patient and foetal radiation doses due to endoscopic retrograde cholangiopancreatography (ERCP) procedures in a pregnant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2678486" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The effect of embryonic and fetal exposure to x-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2678486" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The effect of embryonic and fetal exposure to x-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33269328" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term follow-up after fetal radiation exposure during endoscopic retrograde cholangiopancreatography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34399965" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : American Society for Gastrointestinal Endoscopy radiation and fluoroscopy safety in GI endoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7639227" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Endoscopic retrograde cholangiopancreatography in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22438152" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Radiation protection in digestive endoscopy: European Society of Digestive Endoscopy (ESGE) guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23951391" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fetal radiation exposure: Is monitoring really needed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20653072" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Role of endoscopic ultrasound/SpyScope in diagnosis and treatment of choledocholithiasis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21269945" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : SpyGlass cholangioscopy for management of choledocholithiasis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33532547" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Multicenter experience with digital single-operator cholangioscopy in pregnant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30364767" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Systematic review of safety and efficacy of therapeutic endoscopic-retrograde-cholangiopancreatography during pregnancy including studies of radiation-free therapeutic endoscopic-retrograde-cholangiopancreatography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27773807" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outcomes of Pregnancies for Women Undergoing Endoscopy While They Were Pregnant: A Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25088919" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
